Cargando…
The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy
BACKGROUND: Chemotherapy-induced amenorrhea (CIA) is common in young breast cancer patients. The incidence of CIA associated with regimens involving epirubicin and taxane was not well known. Furthermore, previous studies suggested leucopenia and amenorrhea may reflect inter-individual variations in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353923/ https://www.ncbi.nlm.nih.gov/pubmed/22615953 http://dx.doi.org/10.1371/journal.pone.0037249 |
_version_ | 1782233119203524608 |
---|---|
author | Zhou, Wenbin Ding, Qiang Liang, Xiuqing He, Zhongyuan Zha, Xiaoming Liu, Xiaoan Wang, Shui |
author_facet | Zhou, Wenbin Ding, Qiang Liang, Xiuqing He, Zhongyuan Zha, Xiaoming Liu, Xiaoan Wang, Shui |
author_sort | Zhou, Wenbin |
collection | PubMed |
description | BACKGROUND: Chemotherapy-induced amenorrhea (CIA) is common in young breast cancer patients. The incidence of CIA associated with regimens involving epirubicin and taxane was not well known. Furthermore, previous studies suggested leucopenia and amenorrhea may reflect inter-individual variations in pharmacokinetics. The purpose of this study was to investigate the association between leucopenia after first cycle of chemotherapy and CIA in young breast cancer patients receiving epirubicin and taxane based chemotherapy. Furthermore, the incidence of CIA was also assessed. METHODOLOGY AND PRINCIPAL FINDINGS: Between October 2008 and March 2010, 186 consecutive premenopausal patients, treated with epirubicin and taxane based chemotherapy, were recruited. Information about CIA was collected by telephone and out-patient clinic. Of these 186 patients, data from 165 patients were included and analyzed. Of all 165 patients, CIA occurred in 72 patients (43.64%). In multivariate analysis, age older than 40 y (OR: 16.10, 95% CI: 6.34–40.88, P<0.001) and previous childbearing (OR: 3.17, 95% CI: 1.06–9.47, P = 0.038) were significantly associated with probability of CIA. Compared to patients treated without taxane, patients treated with taxane-contained regimens did not have a significantly higher rate of CIA (P>0.05). The rate of CIA in leucopenia group (52.56%) was significantly higher than that in normal leukocyte group (34.62%) (P = 0.024). In patients treated with a FEC regimen (cyclophosphamide, epirubicin and 5-fluorouracil), the rate of CIA in leucopenia group (59.57%) was significantly higher than that in normal leukocyte group (36.84%) (P = 0.037). CONCLUSIONS: Age at diagnosis and previous childbearing were both found to significantly increase the risk of CIA, whereas additional taxane was not associated with increased rate of CIA. Importantly, leucopenia after first cycle of chemotherapy was associated with increased risk of CIA, which suggested that leucopenia may be an early predictor of chemotherapy-induced infertility. |
format | Online Article Text |
id | pubmed-3353923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33539232012-05-21 The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy Zhou, Wenbin Ding, Qiang Liang, Xiuqing He, Zhongyuan Zha, Xiaoming Liu, Xiaoan Wang, Shui PLoS One Research Article BACKGROUND: Chemotherapy-induced amenorrhea (CIA) is common in young breast cancer patients. The incidence of CIA associated with regimens involving epirubicin and taxane was not well known. Furthermore, previous studies suggested leucopenia and amenorrhea may reflect inter-individual variations in pharmacokinetics. The purpose of this study was to investigate the association between leucopenia after first cycle of chemotherapy and CIA in young breast cancer patients receiving epirubicin and taxane based chemotherapy. Furthermore, the incidence of CIA was also assessed. METHODOLOGY AND PRINCIPAL FINDINGS: Between October 2008 and March 2010, 186 consecutive premenopausal patients, treated with epirubicin and taxane based chemotherapy, were recruited. Information about CIA was collected by telephone and out-patient clinic. Of these 186 patients, data from 165 patients were included and analyzed. Of all 165 patients, CIA occurred in 72 patients (43.64%). In multivariate analysis, age older than 40 y (OR: 16.10, 95% CI: 6.34–40.88, P<0.001) and previous childbearing (OR: 3.17, 95% CI: 1.06–9.47, P = 0.038) were significantly associated with probability of CIA. Compared to patients treated without taxane, patients treated with taxane-contained regimens did not have a significantly higher rate of CIA (P>0.05). The rate of CIA in leucopenia group (52.56%) was significantly higher than that in normal leukocyte group (34.62%) (P = 0.024). In patients treated with a FEC regimen (cyclophosphamide, epirubicin and 5-fluorouracil), the rate of CIA in leucopenia group (59.57%) was significantly higher than that in normal leukocyte group (36.84%) (P = 0.037). CONCLUSIONS: Age at diagnosis and previous childbearing were both found to significantly increase the risk of CIA, whereas additional taxane was not associated with increased rate of CIA. Importantly, leucopenia after first cycle of chemotherapy was associated with increased risk of CIA, which suggested that leucopenia may be an early predictor of chemotherapy-induced infertility. Public Library of Science 2012-05-16 /pmc/articles/PMC3353923/ /pubmed/22615953 http://dx.doi.org/10.1371/journal.pone.0037249 Text en Zhou et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zhou, Wenbin Ding, Qiang Liang, Xiuqing He, Zhongyuan Zha, Xiaoming Liu, Xiaoan Wang, Shui The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy |
title | The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy |
title_full | The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy |
title_fullStr | The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy |
title_full_unstemmed | The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy |
title_short | The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy |
title_sort | risk of amenorrhea is related to chemotherapy-induced leucopenia in breast cancer patients receiving epirubicin and taxane based chemotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353923/ https://www.ncbi.nlm.nih.gov/pubmed/22615953 http://dx.doi.org/10.1371/journal.pone.0037249 |
work_keys_str_mv | AT zhouwenbin theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT dingqiang theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT liangxiuqing theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT hezhongyuan theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT zhaxiaoming theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT liuxiaoan theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT wangshui theriskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT zhouwenbin riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT dingqiang riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT liangxiuqing riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT hezhongyuan riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT zhaxiaoming riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT liuxiaoan riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy AT wangshui riskofamenorrheaisrelatedtochemotherapyinducedleucopeniainbreastcancerpatientsreceivingepirubicinandtaxanebasedchemotherapy |